CytomX Therapeutics (CTMX) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evolus (EOLS) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 4.8% versus a loss of 47.7%. Over five years, EOLS leads with a +14.4% price change compared with -69.9% for CTMX. CytomX Therapeutics is the larger company by market cap ($442.5 million vs $431.5 million), about 1.0 times the size, while Evolus is growing revenue faster (+11.6% vs -44.8%).
Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -22.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | EOLS |
|---|---|---|
| Share price | $2.03 | $6.52 |
| Market cap | $442.55M | $431.55M |
| 1-day change | -0.98% | -6.86% |
| YTD return | -52.35% | -1.95% |
| 1-year return | -47.68% | -4.82% |
| 5-year return | -69.93% | +14.39% |
| Forward P/E | — | 22.68 |
| EPS (TTM) | $-0.51 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $76.20M | $297.18M |
| Revenue growth (YoY) | -44.82% | +11.61% |
| Net income (latest FY) | $-17.37M | $-51.64M |
| Gross margin | — | 66.33% |
| Operating margin | -29.35% | -10.99% |
| Net margin | -22.79% | -17.38% |
| 52-week high | $8.21 | $9.31 |
| 52-week low | $1.87 | $3.86 |
| Distance from 52-week high | -75.27% | -29.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +509.85% | +136.20% |
| Average volume | 4.27M | 925.77K |
| Shares outstanding | 218.00M | 66.19M |
| Employees | 69 | 365 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed CTMX by 42.9 percentage points over the past year.
- Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -22.8 cents for CytomX Therapeutics.
- Evolus grew revenue faster in its latest fiscal year (+11.61% vs -44.82%).
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
CTMX vs EOLS FAQ
Which is bigger, CytomX Therapeutics or Evolus?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $442.55M compared with $431.55M for Evolus (EOLS).
Which stock has performed better over the past year, CTMX or EOLS?
EOLS returned -4.82% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.